These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 17003454)

  • 1. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV; Steén B; Seregard S; Kvanta A
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
    Retina; 2006; 26(5):495-511. PubMed ID: 16770255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
    Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
    Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
    Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
    Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Chan CK; Meyer CH; Gross JG; Abraham P; Nuthi AS; Kokame GT; Lin SG; Rauser ME; Kaiser PK
    Retina; 2007 Jun; 27(5):541-51. PubMed ID: 17558314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.